NCT02652234

Study of Endostar Subcutaneous Injection in NSCLC

A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	Endostar	Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
DRUG	Chemotherapy

Timeline

• Start date: 2015-08-01
• Primary completion: 2016-06-01
• Completion: 2016-09-01
• First posted: 2016-01-11
• Last updated: 2016-01-11

Locations

1 site across 1 country: China